FNCH vs. KRBP, GMDAQ, ALBT, TCON, ELOX, WINT, FRTX, XXII, ACORQ, and TTNP
Should you be buying Finch Therapeutics Group stock or one of its competitors? The main competitors of Finch Therapeutics Group include Kiromic BioPharma (KRBP), Gamida Cell (GMDAQ), Avalon GloboCare (ALBT), TRACON Pharmaceuticals (TCON), Eloxx Pharmaceuticals (ELOX), Windtree Therapeutics (WINT), Fresh Tracks Therapeutics (FRTX), 22nd Century Group (XXII), Acorda Therapeutics (ACORQ), and Titan Pharmaceuticals (TTNP).
Kiromic BioPharma (NASDAQ:KRBP) and Finch Therapeutics Group (NASDAQ:FNCH) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, community ranking, valuation, media sentiment, earnings, analyst recommendations and profitability.
Finch Therapeutics Group's return on equity of 0.00% beat Kiromic BioPharma's return on equity.
In the previous week, Finch Therapeutics Group's average media sentiment score of 0.00 equaled Kiromic BioPharma'saverage media sentiment score.
Finch Therapeutics Group received 9 more outperform votes than Kiromic BioPharma when rated by MarketBeat users. Likewise, 52.63% of users gave Finch Therapeutics Group an outperform vote while only 50.00% of users gave Kiromic BioPharma an outperform vote.
Kiromic BioPharma has a beta of 1.98, indicating that its stock price is 98% more volatile than the S&P 500. Comparatively, Finch Therapeutics Group has a beta of 0.46, indicating that its stock price is 54% less volatile than the S&P 500.
10.9% of Kiromic BioPharma shares are held by institutional investors. Comparatively, 21.8% of Finch Therapeutics Group shares are held by institutional investors. 3.3% of Kiromic BioPharma shares are held by company insiders. Comparatively, 44.9% of Finch Therapeutics Group shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Kiromic BioPharma has higher earnings, but lower revenue than Finch Therapeutics Group. Kiromic BioPharma is trading at a lower price-to-earnings ratio than Finch Therapeutics Group, indicating that it is currently the more affordable of the two stocks.
Summary
Finch Therapeutics Group beats Kiromic BioPharma on 7 of the 11 factors compared between the two stocks.
Get Finch Therapeutics Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for FNCH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding FNCH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Finch Therapeutics Group Competitors List
Related Companies and Tools
